Cancer prevalence among large cohort of individuals with down syndrome: Implications for screening guidelines

Authors

• Veronica Fitzpatrick, Advocate Health - MidwestFollow
• Akaninyene Noah, Advocate Health - MidwestFollow
• Anne Rivelli, Advocate Health - MidwestFollow
• Rachel Johnson, Advocate Health - MidwestFollow
• Melissa Zak, Advocate Health - Midwest
• Joaquin Espinosa, Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
• Brian Chicoine, Advocate Health - MidwestFollow

Recommended Citation

Fitzpatrick V, Noah A, Rivelli A, et al. Cancer Prevalence Among Large Cohort of Individuals With Down Syndrome: Implications for Screening Guidelines. Cancer Med. 2026;15(6):e72007. doi:10.1002/cam4.72007

Affiliations

Advocate Medical Group Adult Down Syndrome Center, Park Ridge, IL

Abstract

Introduction: It is known that individuals with Down syndrome (DS) have a significantly different spectrum of malignancies and neoplasms. Research shows that most solid tumors are less common among individuals with DS compared to the general population, even when adjusted for age. Conversely, individuals with DS are more likely to develop leukemia and testicular cancer. However, very little of this research has been conducted with a US-based population or on large sample sizes.

Methods: This retrospective cohort study analyzed 24 years of EHR data from 5895 unique individuals with DS seen in a Midwestern US health system, with the largest designated DS clinic in the US. We calculated the point prevalence of each cancer type, based on ICD-10 coding, in our DS cohort, examined co-occurrence patterns, and compared prevalence within our sample to the US general population using SEER data from 2022.

Results: Individuals with DS have significantly lower odds of cancer than the general population (OR = 0.88 (0.77-0.99)). Our cohort was 50.2% less likely to have skin cancer, 80.1% less likely to have cervical cancer, 91% less likely to have prostate cancer, and 90% less likely to have breast cancer. Zero people in our DS cohort had lung cancer. Conversely, our cohort was more likely to have leukemia and testicular cancer.

Conclusion: The differences in prevalences indicate a need to consider modification of the cancer screening recommendations for people with DS and inclusion of the information in shared-decision making conversations with the patient and their family.

Type

Article

PubMed ID

42252503